Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Depreciation & Amortization (CF) (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Depreciation & Amortization (CF) for 2 consecutive years, with $418000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 14.52% to $418000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, down 3.44% year-over-year, with the annual reading at $1.7 million for FY2025, 3.44% down from the prior year.
  • Depreciation & Amortization (CF) hit $418000.0 in Q4 2025 for Prelude Therapeutics, down from $425000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $489000.0 in Q4 2024 to a low of $405000.0 in Q3 2024.